These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30457960)

  • 1. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
    Smith KE; Staton M
    Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 3. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
    Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
    J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of Synthetic Cannabinoid and Cathinone Use among a Drug-Using Offender Sample, 2013-2015.
    Smith KE; Bunting AM; Staton M; Walker R; Shalash S; Winston E; Pangburn K
    J Psychoactive Drugs; 2017; 49(5):436-445. PubMed ID: 28813207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Use of Synthetic Cannabinoids, Synthetic Opioids, and Other Psychoactive Drug Groups among High-risk Drug Users.
    Shapira B; Berkovitz R; Rosca P; Neumark Y
    J Psychoactive Drugs; 2020; 52(4):334-343. PubMed ID: 32345134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
    Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
    Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Correlates of Electronic Cigarette Use Among a Clinical Sample of Polysubstance Users in Kentucky: Long Live the Cigarette?
    Elin Smith K
    Subst Use Misuse; 2019; 54(2):225-235. PubMed ID: 30409060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Future of Substance Abuse Now: Relationships among Adolescent Use of Vaping Devices, Marijuana, and Synthetic Cannabinoids.
    Tai H; Swartz MD; Marsden D; Perry CL
    Subst Use Misuse; 2021; 56(2):192-204. PubMed ID: 33412950
    [No Abstract]   [Full Text] [Related]  

  • 10. Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use.
    Winkelman TNA; Chang VW; Binswanger IA
    JAMA Netw Open; 2018 Jul; 1(3):e180558. PubMed ID: 30646016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic cannabinoid use among college students.
    Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD
    Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
    Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
    Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
    Zaurova M; Hoffman RS; Vlahov D; Manini AF
    J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cloud on the horizon-a survey into the use of electronic vaping devices for recreational drug and new psychoactive substance (NPS) administration.
    Blundell M; Dargan P; Wood D
    QJM; 2018 Jan; 111(1):9-14. PubMed ID: 29025078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.
    Smith KE; Lawson T
    Drug Alcohol Depend; 2017 Nov; 180():340-348. PubMed ID: 28950240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
    Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
    Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
    Palamar JJ; Su MK; Hoffman RS
    Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlates of specialty substance use treatment among adults with opioid use disorders.
    Romo E; Ulbricht CM; Clark RE; Lapane KL
    Addict Behav; 2018 Nov; 86():96-103. PubMed ID: 29551551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.